Endologix (ELGX) has an average broker rating of 1.29, which is interpreted as a Strong Buy, as rated by 7 equity analysts. Nonetheless, 6 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Endologix (ELGX) : Average target price received by Endologix (ELGX) is $15.07 with an expected standard deviation of $1.43. The most aggressive target on the stock is $16, whereas the most downbeat target is $12. 7 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy. Also, RBC Capital downgrades its rating on Endologix (NASDAQ:ELGX). Analysts at the RBC Capital have a current rating of Sector Perform on the shares. The shares were previously rated Outperform. The rating by the firm was issued on August 3, 2016.
Endologix (NASDAQ:ELGX): The stock opened at $12.29 and touched an intraday high of $12.61 on Wednesday. During the day, the stock corrected to an intraday low of $12.24, however, the bulls stepped in and pushed the price higher to close in the green at $12.6 with a gain of 1.94% for the day. The total traded volume for the day was 594,111. The stock had closed at $12.36 in the previous trading session.
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Companys products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Companys EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.